文献速递胸部肿瘤

多西他赛联合巴维昔单抗治疗经治晚期非鳞非小细胞肺癌的随机III期研究

Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer.
PubMed 文献 · Ann Oncol · 2018-01-01

这项随机III期试验评估了巴维昔单抗联合多西他赛对比多西他赛单药在经治晚期非鳞非小细胞肺癌患者中的疗效。共纳入597例患者,主要终点总生存期在两组间无显著差异(10.5个月 vs 10.9个月,HR 1.06,P=0.533)。联合治疗未显著增加毒性,但在高β2GP1水平及后续接受免疫检查点抑制剂的患者中观察到潜在获益趋势,需进一步研究。

要点

  • 巴维昔单抗联合多西他赛未改善经治晚期非鳞NSCLC患者的总生存期。
  • 联合治疗的安全性可控,两组毒性相似。
  • 高β2GP1水平及后续免疫治疗患者中的潜在获益需进一步验证。

核心结论

  • 巴维昔单抗联合多西他赛在经治晚期非鳞NSCLC中不优于多西他赛单药。
  • 联合治疗未显著增加毒性。
  • 高β2GP1水平及后续接受免疫检查点抑制剂患者的潜在获益需进一步研究。

研究设计与样本

  • 随机、双盲、III期试验,纳入597例经铂类双药化疗后进展的晚期非鳞NSCLC患者。
  • 患者1:1随机接受多西他赛联合巴维昔单抗3 mg/kg每周一次或安慰剂,最多6个21天周期。
  • 主要终点为总生存期(OS)。

主要发现

  • 中位OS:巴维昔单抗组10.5个月 vs 安慰剂组10.9个月(HR 1.06;95%CI 0.88-1.29;P=0.533)。
  • 无进展生存期无差异(HR 1.00;95%CI 0.82-1.22;P=0.990)。
  • 基线血清β2GP1≥200 µg/ml患者中,OS趋势利于巴维昔单抗组(HR 0.82;95%CI 0.63-1.06;P=0.134)。
  • 后续接受免疫检查点抑制剂的患者中,OS利于巴维昔单抗组(HR 0.46;95%CI 0.26-0.81;P=0.006)。

临床怎么用

  • 不推荐在经治晚期非鳞NSCLC中常规使用巴维昔单抗联合多西他赛。
  • 高β2GP1水平或后续计划免疫治疗的患者可考虑临床试验背景下进一步评估。

局限性

  • 亚组分析(β2GP1水平、后续免疫治疗)为探索性,样本量有限,需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bavituximab is a monoclonal antibody that targets phosphatidylserine in the presence of β2 glycoprotein 1 (β2GP1) to exert an antitumor immune response. This phase III trial determined the efficacy of bavituximab combined with docetaxel in patients with previously treated advanced non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Key eligibility criteria included advanced non-squamous NSCLC with disease progression after treatment with platinum-based doublet chemotherapy, evidence of disease control after at least two cycles of first-line therapy, presence of measurable disease, ECOG performance status 0 or 1, adequate bone marrow and organ function, and no recent history of clinically significant bleeding. Eligible patients were randomized 1 : 1 to receive up to six 21-day cycles of docetaxel plus either weekly bavituximab 3 mg/kg or placebo until progression or toxicity. The primary end point was overall survival (OS). RESULTS: A total of 597 patients were enrolled. Median OS was 10.5 months in the docetaxel + bavituximab arm and was 10.9 months in the docetaxel + placebo arm (HR 1.06; 95% CI 0.88-1.29; P = 0.533). There was no difference in progression-free survival (HR 1.00; 95% CI 0.82-1.22; P = 0.990). Toxicities were manageable and similar between arms. In subset analysis, among patients with high baseline serum β2GP1 levels ≥200 µg/ml, a nonsignificant OS trend favored the bavituximab arm (HR 0.82; 95% CI 0.63-1.06; P = 0.134). Among patients who received post-study immune checkpoint inhibitor therapy, OS favored the bavituximab arm (HR 0.46; 95% CI 0.26-0.81; P = 0.006). CONCLUSIONS: The combination of bavituximab plus docetaxel is not superior to docetaxel in patients with previously treated advanced NSCLC. The addition of bavituximab to docetaxel does not meaningfully increase toxicity. The potential benefit of bavituximab observed in patients with high β2GP1 levels and in patients subsequently treated with immune checkpoint inhibitors requires further investigation. CLINICAL TRIAL NUMBER: NCT01999673.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Gerber DE, Horn L, Boyer M, et al. Randomized phase III study of docetaxel plus bavituximab in previously treated advanced non-squamous non-small-cell lung cancer. Ann Oncol. 2018. PMID: 29767677. doi:10.1093/annonc/mdy177

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。